scholarly journals Symptomatic Hyponatremia after Continuous Infusion of Vasopressin: A Case Report

2021 ◽  
Vol 8 (1) ◽  
pp. 1-4
Author(s):  
Rafiqul Islam ◽  
Keyword(s):  
Case Report ◽  
Continuous Infusion ◽  
Antidiuretic Hormone ◽  
Arginine Vasopressin ◽  
Posterior Pituitary

Arginine Vasopressin (AVP), also known as antidiuretic hormone, is a endogenously secreted peptide by the posterior pituitary in response to hyperosmolar plasma or systemic hypoperfusion states.

scholarly journals Masks of Schwartz-Bartter Syndrome clinical pictures: a case report

2008 ◽  
Vol 5 (2) ◽  
pp. 42-44
Author(s):  
E A Pigarova ◽  
L K Dzeranova ◽  
L Ya Rozhinskaya
Keyword(s):  
Case Report ◽  
Diabetes Insipidus ◽  
Antidiuretic Hormone ◽  
Marked Reduction ◽  
Bartter Syndrome ◽  
Posterior Pituitary ◽  
Inappropriate Secretion ◽  
Excessive Secretion ◽  
Clinical Pictures ◽  
Specific Symptoms

Schwartz-Bartter Syndrome (synonyms: syndrome of inappropriate secretion of antidiuretic hormone syndrome of inappropriate secretion of vasopressin, anti-diabetes insipidus) - this is a rare disease characterized by excessive secretion of antidiuretic hormone (ADH) from the posterior pituitary, or other source, resulting in developing hyponatremia and water intoxication. Hyponatremia dilutions at Schwartz-Bartter Syndrome is usually non-specific symptoms, such as headache, nausea, vomiting and confusion. Marked reduction in blood sodium levels may lead to seizures or even coma.

Episodic secretion of arginine vasopressin.

1977 ◽  
Vol 233 (1) ◽  
pp. E32
Author(s):  
R E Weitzman ◽  
D A Fisher ◽  
J J DiStefano ◽  
C M Bennett
Keyword(s):  
Continuous Infusion ◽  
Arginine Vasopressin ◽  
Bolus Injection ◽  
Posterior Pituitary ◽  
Short Term ◽  
Water Diuresis ◽  
Osmotic Stimulation ◽  
Plasma Arginine ◽  
Frequent Sampling ◽  
Stimulation Of

The plasma arginine vasopressin (pAVP) response to osmotic stimulation was studied in dogs and sheep by sampling at frequent intervals during steady-state dehydration and during water diuresis. Frequent sampling also was conducted after continuous infusion or bolus injection of 5 or 20 g/100 ml NaCl. A pulsatile pattern of pAVP was observed after such infusions or injections and in some animals after water deprivation. This pattern was not seen after water loading or in mildly dehydrated animals. The short term changes in pAVP during continuous infusion of 5 g/100 ml NaCl could not be correlated with variations in plasma tonicity. Rather, they appeared to reflect discontinuous hypothalamic posterior pituitary release of AVP. Thirst was evoked by a lower dose of 5 g/100 ml NaCl than was required for consistent stimulation of pAVP release, and the thirst response frequently was observed prior to the peak AVP response after bolus injection of 5 and 20 g/100 ml NaCl.

scholarly journals Cryo–electron microscopy structure of the antidiuretic hormone arginine-vasopressin V2 receptor signaling complex

2021 ◽  
Vol 7 (21) ◽  
pp. eabg5628
Author(s):  
Julien Bous ◽  
Hélène Orcel ◽  
Nicolas Floquet ◽  
Cédric Leyrat ◽  
Joséphine Lai-Kee-Him ◽  
...  
Keyword(s):  
Electron Microscopy ◽  
Antidiuretic Hormone ◽  
Arginine Vasopressin ◽  
Molecular Mechanisms ◽  
Particle Analysis ◽  
Resonance Spectroscopy ◽  
Gpcr Signaling ◽  
Signaling Complex ◽  
Cryo Electron Microscopy ◽  
V2 Receptor

The antidiuretic hormone arginine-vasopressin (AVP) forms a signaling complex with the V2 receptor (V2R) and the Gs protein, promoting kidney water reabsorption. Molecular mechanisms underlying activation of this critical G protein–coupled receptor (GPCR) signaling system are still unknown. To fill this gap of knowledge, we report here the cryo–electron microscopy structure of the AVP-V2R-Gs complex. Single-particle analysis revealed the presence of three different states. The two best maps were combined with computational and nuclear magnetic resonance spectroscopy constraints to reconstruct two structures of the ternary complex. These structures differ in AVP and Gs binding modes. They reveal an original receptor-Gs interface in which the Gαs subunit penetrates deep into the active V2R. The structures help to explain how V2R R137H or R137L/C variants can lead to two severe genetic diseases. Our study provides important structural insights into the function of this clinically relevant GPCR signaling complex.

A Case Report of Syndrome of Inappropriate Secretion of Antidiuretic Hormone With Marked Edema Due to Administration of Hypertonic Saline

2007 ◽  
Vol 11 (4) ◽  
pp. 309-313 ◽  
Author(s):  
Hiroto Maeda ◽  
Kazuhiko Tsuruya ◽  
Hideki Yotsueda ◽  
Masatomo Taniguchi ◽  
Masanori Tokumoto ◽  
...  
Keyword(s):  
Case Report ◽  
Antidiuretic Hormone ◽  
Hypertonic Saline ◽  
Inappropriate Secretion

scholarly journals Midazolam for treatment of refractory neonatal seizures: a case report

1994 ◽  
Vol 52 (2) ◽  
pp. 260-262 ◽  
Author(s):  
José Luiz Dias Gherpelli ◽  
Francisco José C. Luccas ◽  
Israel Roitman ◽  
Eduardo Juan Troster
Keyword(s):  
Case Report ◽  
Status Epilepticus ◽  
Continuous Infusion ◽  
Seizure Control ◽  
Neonatal Period ◽  
Hyaline Membrane Disease ◽  
Water Soluble ◽  
Neonatal Seizures ◽  
Hyaline Membrane ◽  
Ischemic Encephalopathy

Midazolam is a short-acting water soluble benzodiazepine that has been used with an increasing frequency in the last years. Although there are reports on its use in status epilepticus, there is none in the neonatal period. A pre-term (35 w) AGA newborn infant with a severe hypoxic-ischemic encephalopathy secondary to grade ED hyaline membrane disease developed status epilepticus in the first 6 hours of life and was successfully treated with midazolam after phenobarbital and phenytoin failed to achieve seizure control. Dosage schedule was 0.2 mg/kg IV, followed by continuous infusion of 0.025 mg/kg/h. Midazolam is an effective drug for neonatal status epilepticus and more experience should accumulate before it can be routinely employed in the neonatal period. This case shows that it is a possible option before using more dangerous drugs, such as thionembutal.

Impairment of osmotically stimulated AVP release in patients with primary polydipsia

1993 ◽  
Vol 265 (6) ◽  
pp. R1247-R1252 ◽  
Author(s):  
A. M. Moses ◽  
B. Clayton
Keyword(s):  
Diabetes Insipidus ◽  
Arginine Vasopressin ◽  
Plasma Osmolality ◽  
Normal Subjects ◽  
Urine Concentration ◽  
Published Data ◽  
Posterior Pituitary ◽  
Primary Polydipsia ◽  
Number Of Factors

The secretion of arginine vasopressin (AVP) from the posterior pituitary is primarily and finely regulated by the osmolality of plasma. Even though a number of factors alter osmolality-induced release of AVP, there are no published data in humans that have addressed the role of chronic overhydration on this phenomenon. To address this problem we have identified eight patients with primary polydipsia using criteria not involving measurement of AVP, and have subjected them to standardized infusions of hypertonic saline. These patients had less AVP in both plasma and urine in relation to plasma osmolality than was found in normal subjects. In addition, their rate of rise of plasma and urine AVP was less than in normal subjects. Their osmotic threshold for AVP release may have been higher than normal. These data demonstrate that chronic overhydration in humans downregulates the release of AVP in response to hypertonicity. This phenomenon may explain the impairment of urine concentration in patients with primary polydipsia and emphasizes the basis of the difficulty that may occur clinically in differentiating between patients with primary polydipsia and partial central diabetes insipidus.

Sign in / Sign up

Export Citation Format

Share Document